Expression of infectious pancreatic necrosis virus (IPNV) VP2-VP3 fusion protein in Lactobacillus casei and immunogenicity in rainbow trouts

Vaccine

Volumn 30, Issue 10, 2012, Pages 1823-1829

  Li Li, Zhao ^a   Min, Liu ^a   Jun Wei, Ge ^a   Xin Yuan, Qiao ^a   Yi Jing, Li ^a   Di Qiu, Liu ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

Infectious pancreatic necrosis virus; Lactobacillus; Mucosal vaccine; Rainbow trout; VP2 VP3 fusion

Indexed keywords

IMMUNOGLOBULIN M; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS VACCINE; VP2 VP3 FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FUSION GENE; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; INFECTIOUS PANCREATIC NECROSIS VIRUS; INOCULATION; JUVENILE ANIMAL; LACTOBACILLUS; LACTOBACILLUS CASEI; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAINBOW TROUT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; VIRUS INFECTION; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIRNAVIRIDAE INFECTIONS; FISH DISEASES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN M; INFECTIOUS PANCREATIC NECROSIS VIRUS; LACTOBACILLUS CASEI; NEUTRALIZATION TESTS; ONCORHYNCHUS MYKISS; RECOMBINANT FUSION PROTEINS; VIRAL LOAD; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84857451899     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.132     Document Type: Article

References (45)

1. Petit S., Lejal N., Huet J.C., Delmas B. Active residues and viral substrate cleavage sites of the protease of the birnavirus infectious pancreatic necrosis virus. J Virol 2000, 74(March (5)):2057-2066.
2. Duncan R., Dobos P. The nucleotide sequence of infectious pancreatic necrosis virus (IPNV) dsRNA segment A reveals one large ORF encoding a precursor polyprotein. Nucleic Acids Res 1986, 14(14):5934.
3. Fridholm H., Eliasson L., Everitt E. Immunogenicity properties of authentic and heterologously synthesized structural protein VP2 of infectious pancreatic necrosis virus. Viral Immunol 2007, 20(December (4)):635-648.
4. Frost P., BoRSHEIM K., Endresen C. Analysis of the antibody response in Atlantic salmon against recombinant VP2 of infectious pancreatic necrosis virus (IPNV). Fish Shellfish Immunol 1998, 8(6):447-456.
5. Tarrab E., Berthiaume L., Grothe S., O'Connor-McCourt M., Heppell J., Lecomte J. Evidence of a major neutralizable conformational epitope region on VP2 of infectious pancreatic necrosis virus. J Gen Virol 1995, 76(3):551.
6. Dobos P., Roberts T.E. The molecular biology of infectious pancreatic necrosis virus: a review. Can J Microbiol 1983, 29(April (4)):377-384.
7. Rodriguez S., Alonso M., Perez-Prieto S. Detection of infectious pancreatic necrosis virus (IPNV) from leukocytes of carrier rainbow trout Oncorhynchus mykiss. Fish Pathol 2001, 36(3):139-146.
8. Cutrin J., Lopez-Vozquez C., Olveira J., Castro S., Dopazo C., Bandin I. Isolation in cell culture and detection by PCR-based technology of IPNV-like virus from leucocytes of carrier turbot, Scophthalmus maximus (L.). J Fish Dis 2005, 28(12):713-722.
9. Garcia J., Urquhart K., Ellis A. Infectious pancreatic necrosis virus establishes an asymptomatic carrier state in kidney leucocytes of juvenile Atlantic cod, Gadus morhua L. J Fish Dis 2006, 29(7):409-413.
10. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987, 7(July (4)):265-276.
11. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992, 10(2):75-88.
12. Staats H.F., Jackson R.J., Marinaro M., Takahashi I., Kiyono H., McGhee J.R. Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol 1994, 6(August (4)):572-583.
13. Russell-Jones G.J. Oral vaccine delivery. J Control Release 2000, 65(March (1-2)):49-54.
14. Chen H. Recent advances in mucosal vaccine development. J Control Release 2000, 67(July (2-3)):117-128.
15. Dhar A.K., Bowers R.M., Rowe C.G., Allnutt F.C. Expression of a foreign epitope on infectious pancreatic necrosis virus VP2 capsid protein subviral particle (SVP) and immunogenicity in rainbow trout. Antiviral Res 2010, 85(March (3)):525-531.
16. de las Heras A.I., Rodriguez Saint-Jean S., Perez-Prieto S.I. Immunogenic and protective effects of an oral DNA vaccine against infectious pancreatic necrosis virus in fish. Fish Shellfish Immunol 2010, 28(April (4)):562-570.
17. de Las Heras A.I., Perez Prieto S.I., Rodriguez Saint-Jean S. In vitro and in vivo immune responses induced by a DNA vaccine encoding the VP2 gene of the infectious pancreatic necrosis virus. Fish Shellfish Immunol 2009, 27(August (2)):120-129.
18. Allnutt F.C., Bowers R.M., Rowe C.G., Vakharia V.N., LaPatra S.E., Dhar A.K. Antigenicity of infectious pancreatic necrosis virus VP2 subviral particles expressed in yeast. Vaccine 2007, 25(June (26)):4880-4888.
19. Liu D., Wang X., Ge J., Liu S., Li Y. Comparison of the immune responses induced by oral immunization of mice with Lactobacillus casei-expressing porcine parvovirus VP2 and VP2 fused to Escherichia coli heat-labile enterotoxin B subunit protein. Comp Immunol Microbiol Infect Dis 2011, 34(January (1)):73-81.
20. Hou X.L., Yu L.Y., Liu J., Wang G.H. Surface-displayed porcine epidemic diarrhea viral (PEDV) antigens on lactic acid bacteria. Vaccine 2007, 26(1):24-31.
21. Wei C.H., Liu J.K., Hou X.L., Yu L.Y., Lee J.S., Kim C.J. Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99. Vaccine 2010, 28(May (24)):4113-4118.
22. Villena J., Salva S., Agüero G., Alvarez S. Immunomodulatory and protective effect of probiotic Lactobacillus casei against Candida albicans infection in malnourished mice. Microbiol Immunol 2011, 55(6):434-445.
23. Claassen E., Van Winsen R., Posno M., Boersma W. New and safe oral live vaccines based on Lactobacillus. Adv Exp Med Biol 1995, 371:1553.
24. Pouwels P.H., Leer R.J., Boersma W.J.A. The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens. J Biotechnol 1996, 44(1-3):183-192.
25. Galdeano C.M., Perdigon G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 2006, 13(2):219.
26. Ogawa T., Asai Y., Sakamoto H., Yasuda K. Oral immunoadjuvant activity of Lactobacillus casei subsp. casei in dextran-fed layer chickens. Br J Nutr 2006, 95(February (2)):430-434.
27. Ho P.S., Kwang J., Lee Y.K. Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production. Vaccine 2005, 23(February (11)):1335-1342.
28. Cortes-Perez N.G., Bermudez-Humaran L.G., Le Loir Y., Rodriguez-Padilla C., Gruss A., Saucedo-Cardenas O., et al. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 2003, 229(December (1)):37-42.
29. Liu M., Zhao L.-l., Ge J.-w., Ou D., Wand X.-q., Liu Y., et al. Construction of expression system of infectious pancreas necrosis virus VP3 protein in Lactobacillus casei. Freshw Fish 2008, 38(5):30-34. (Chinese).
30. Yigang X.U., Yijing L.I. Construction of recombinant Lactobacillus casei efficiently surface displayed and secreted porcine parvovirus VP2 protein and comparison of the immune responses induced by oral immunization. Immunology 2008, 124(May (1)):68-75.
31. Bowers R.M., Lapatra S.E., Dhar A.K. Detection and quantitation of infectious pancreatic necrosis virus by real-time reverse transcriptase-polymerase chain reaction using lethal and non-lethal tissue sampling. J Virol Methods 2008, 147(February (2)):226-234.
32. Mutwiri G., Watts T., Lew L., Beskorwayne T., Papp Z., Baca-Estrada M.E., et al. Ileal and jejunal Peyer's patches play distinct roles in mucosal immunity of sheep. Immunology 1999, 97(July (3)):455-461.
33. Zhang Y., Pacheco S., Acuna C.L., Switzer K.C., Wang Y., Gilmore X., et al. Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus. Immunology 2002, 105(March (3)):286-294.
34. Reveneau N., Geoffroy M.C., Locht C., Chagnaud P., Mercenier A. Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations. Vaccine 2002, 20(March (13-14)):1769-1777.
35. Seegers J.F.M.L. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 2002, 20(12):508-515.
36. Mannam P., Jones K.F., Geller B.L. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 2004, 72(6):3444.
37. Lee J.S., Poo H., Han D.P., Hong S.P., Kim K., Cho M.W., et al. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol 2006, 80(April (8)):4079-4087.
38. Mercenier A., Muller-Alouf H., Grangette C. Lactic acid bacteria as live vaccines. Curr Issues Mol Biol 2000, 2:17-26.
39. Pouwels P.H., Leer R.J., Shaw M., Heijne den Bak-Glashouwer M.J., Tielen F.D., Smit E., et al. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int J Food Microbiol 1998, 41(2):155-167.
40. Temin H.M. Overview of biological effects of addition of DNA molecules to cells. Dev Biol Stand 1998, 93:37-44.
41. Wolff J.A., Ludtke J.J., Acsadi G., Williams P., Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992, 1(September (6)):363-369.
42. Cernescu C. Nucleic acid vaccines. Rom J Virol 1995, 46(January-June (1-2)):69-73.
43. Smith H.A. Regulatory considerations for nucleic acid vaccines. Vaccine 1994, 12(December (16)):1515-1519.
44. Robertson J.S. Safety considerations for nucleic acid vaccines. Vaccine 1994, 12(December (16)):1526-1528.
45. Moon C.H., Do J.W., Cha S.J., Bang J.D., Park M.A., Yoo D.J., et al. Comparison of the immunogenicity of recombinant VP2 and VP3 of infectious pancreatic necrosis virus and marine birnavirus. Arch Virol 2004, 149(October (10)):2059-2068.